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In the current study, mesoporous carbon (MC) with pore volume (1.53 cm3/g) and pore size
(9.74 nm) was successfully prepared as a carrier for celecoxib (CEL). Celecoxib was loaded
into the pore channels of MC using three different methods: solvent evaporation method,
absorption method and physical mixing method. Solid-state characterization methods,
such as SEM, TEM, BET, DSC and XRD were used to systematically investigate the process of
the drug loading system. Dissolution tests were performed to examine the effects of MC on
the release of CEL. Furthermore, the cytotoxicity, wound healing, migration and invasion
experiments were carried out to measure the contribution of MC to the anti-tumor
metastasis ability of celecoxib on MDA-MB-231 cells. The results showed that CEL could
be kept in a non-crystalline state when they were incorporated into the MC using the
solvent evaporation method or absorption method. The dissolution rate of CEL released
from MCS (Mesoporous carbon e Celecoxib e Solvent evaporation method) and MCA
(Mesoporous carbon e Celecoxib e Absorption evaporation method) was all significantly
higher than that of pure CEL. The cumulative release for MCS within the 5 min was up to
51.86%. MCS enhanced the inhibitory effect of CEL on the migration and invasion of MDA-
MB-231 cells.
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rights reserved., þ86 15904019144 (mobil
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The incidence of breast cancer is gradually increasing and it
has recently become amajor cause of cancer death in women.
The high rate of metastasis of breast cancer remains a major
obstacle to its treatment [1,2]. Celecoxib (CEL), a selective
cyclooxygenase-2 inhibitor, has been used in recent years to
study anti-tumor metastasis [3e5]. This was due to that
cyclooxygenase-2 plays an important role in producing tumor
metastasis [6,7]. However, the poor solubility of CEL seriously
affects its inhibitory effect on tumor metastasis [8]. Many
pharmaceutical techniques have been used to improve the
poor solubility of CEL, such as microemulsions [9], nano-
emulsion [10], and nanoparticles [11]. The emergence of
inorganic porous materials (including porous silica, porous
carbon, and composites.) has opened up a new path for the
development of drug delivery systems [12e14]. Compared
with traditional pharmaceutical carriers, an inorganic carrier
has considerable advantages in terms of particle size, shape
control, stability and surface functionalization [15,16]. There
have been several studies of drug delivery systems involving
mesoporous carbon [17e19]. Mesoporous carbon with a larger
specific surface area, stronger adsorption capacity, greater
pore volume, higher drug loading, and chemical inertness is
more suitable for use as a drug delivery system, compared
with other mesoporous materials.
To my best knowledge, only one paper has been published
using mesoporous carbon as a carrier for CEL [20]. However,
accumulated release of CEL loaded into mesoporous carbon
within the 5 min was just about 40%. The pore size of the
mesoporous carbon reported in the study was 7.0 nm, and the
pore volumewas 1.09 cm3/g. It should be emphasized that pore
size and pore volume of mesoporous carbon were especially
two important factors for release [21e23]. Although meso-
porous carbon with a larger pore size and pore volume had
been synthesized, it had not been studied as a drug delivery
system. So it was a challenge to explore mesoporous carbon
with a larger pore size and volume to be a carrier for CEL.
The purposes of this study were to establish mesoporous
carbon with a large pore volume and large pore size, which
could improve the dissolution rate of CEL significantly. CEL
was loaded into the pore channels of MC using three different
methods: solvent evaporation method, absorption method
and physical mixing method. Solid-state characterization
methods, such as SEM, TEM, BET, DSC and XRD, were used to
systematically investigate the process of the drug loading
system. The release profile of CEL test was examined to
confirm the improved dissolution. Furthermore, the cytotox-
icity, wound healing, migration and invasion tests were car-
ried out to illustrate the contribution of MC to the enhanced
anti-tumor metastasis ability of celecoxib.2. Materials and methods
2.1. Materials
Pluronic block co-polymer F127 was kindly donated by BASF.
Tetraethyl orthosilicate (TEOS), hydrofluoric acid, sulfuric acidand sucrose were purchased from YuWang Reagent Company
(Shandong, China). 1, 3, 5-trimethylbenzene (TMB) was pur-
chased from SigmaeAldrich (St. Louis, MO, USA). Celecoxib
(purity > 99.0%) was supplied from Shenyang Funning Phar-
maceutical Co., Ltd. All other chemicals were used in accor-
dance with the requirements of analytical/spectroscopic/HPLC
grade. Deionized water in all experiments was prepared by ion
exchange.MDA-MB-231breast cancer cells (humanorigin)were
obtained from American Type Culture Collection (ATCC). 3-
(4,5)-dimethylthiahiazo(-z-y1)-3,5-di-phenytetrazoliumromide
(MTT) and crystal violet were purchased from Sigma (St. Louis,
MO, USA).2.2. Preparation and characterization of MC
2.2.1. Preparation of MC
Themesoporous carbon (MC) was prepared usingmesoporous
silica as template. Mesoporous silica was synthesized ac-
cording to the following procedure. A solution was prepared
by dissolving 1.25 g of KCl and 0.5 g of F127 in 30.0 ml of HCl
(2.0 M) at 15 Cwith constant stirring, followed by the addition
of 0.6 g of TMB. After 1 h of stirring at 15 C, 2.0 g TEOS was
added drop by drop to the solution under vigorous stirring.
After 24 h of stirring at 15 C, the suspension was homoge-
nized using an ATS AH100D homogenizer (ATS Engineer Inc.,
Shanghai, China). Then, the obtainedmixture was placed into
a Teflon-lined autoclave for another 24 h at 100 C. As-
synthesized material was filtered and dried at 60 C in the
air. The resulting product was burned out at 600 C for 5 h to
remove surfactant completely. The obtained product (1.0 g)
was first permeated in amixed solution, whichwas composed
of 1.0 g sucrose and 0.1 g H2SO4 in 2.5 g H2O. The obtained gel
was initially carbonized at 80 C for 6 h. Then, the temperature
was increased to 160 C at the speed of 2 C/min for another
6 h. The obtained product was carbonized again at 80 C and
160 C for 6 h after the addition of an aqueous solution
composed of 0.5 g sucrose, 0.06 g H2SO4 and 1.5 g H2O,
respectively. The carbonization of themixture was completed
at 700 C for 3 h at the speed of 3 C/min under N2. Finally, the
carbonesilica composite was mixed with 10% hydrofluoric
acid at 25 C for 48 h to remove the template. Themixture was
filtered, washed with water, and dried at 100 C for 24 h.
2.2.2. Drug loading procedure
2.2.2.1. Solvent evaporation method. The solvent evaporation
method involved soaking and solvent evaporation. MC was
added in a methanol solution of CEL (20 mg/ml) according to a
certain proportion (1:4). Then, the mixture was ultrasonicated
for 30 min and stirred for 24 h at 25 C in a closed container.
Finally, the solvent was evaporated and the precipitated
powder was washed with methanol to remove the drugs on
the surface of the carrier. At last, solid powder was dried at
40 C in the air until no organic solvent residue. Drug-loaded
samples were labeled with MCS.
2.2.2.2. Absorption method. MC (20 mg) was added in a
methanol solution of CEL (20 mg/ml). Then, the mixture was
ultrasonicated for 30 min and stirred for 24 h at 25 C in a
closed container. Finally, the mixture was centrifuged to
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labeled with MCA.
2.2.2.3. Physical mixing method. CEL was mixed with MC ac-
cording to a certain proportion (1:4). The obtained samples
were labeled with MCP.2.3. Characterization techniques
2.3.1. SEM study
The morphology of the samples plated with gold was char-
acterized using a field emission scanning electronmicroscope
(JEOL-6700, Japan).
2.3.2. TEM study
The samples deposited on copper grids were characterized
using TEM (Tecnai G2 20, FEI, USA).
2.3.3. Nitrogen adsorption analysis
Adsorptionedesorption tests were performed on a nitrogen
adsorption analyzer (V-Sorb 2800P, China). The carriers were
degassed to remove physically adsorbed water before
analysis.
2.3.4. DSC analysis
DSC profiles of the samples were recorded from a DSC in-
strument (TA Instruments, Q1000, USA). The temperature
range was 50e200 C at a heating rate of 10 C/min.
2.3.5. XRD analysis
X-ray diffractometer (PW3040/60 PANALYII CALB.V
Netherlands) was used to measure the crystalline character-
istics of samples. The samples were scanned from 5 to
50with a scan rate of 5/min.2.4. Analysis of drug content
The drug loading of CEL was analyzed using ultraviolet (UV)
spectroscopy (UV-2000, Unico, USA), while the detection
wavelength was 254 nm. CEL was separated from samples
with methanol by ultrasonic method. The drug-loading was
calculated using the following equation. Drug-
loading ¼Weight of CEL in sample/Weight of sample.2.5. In vitro release behavior study
Dissolution tests were carried out using a USP II paddle
method with a dissolution tester (KC-8D, Tianjin Guoming
Medical Equipment Co. Ltd.). Phosphate buffer (pH 6.8) was
used as the dissolution media. The dissolution procedure was
as follows, 900 ml of dissolution media in a basket was kept at
37 C and stirred at a rate of 100 rpm. 200 mg samples
(equivalent to 50mg of CEL) were added and performed for 1 h.
5 ml samples were collected at designated intervals (5, 10, 15,
20, 30, 45 and 60 min). The amount of CEL dissolved was
measured by spectroscopy (UV-2000, Unico, USA) at 254 nm.
All tests were performed for six times.2.6. MDA-MB-231 cell experiments
2.6.1. Cellular cytotoxicity assays
MDA-MB-231 cells were propagated in DMEM (high glucose
level) containing 10% fetal bovine serum (GIBCO), 1% sodium
pyrurate, 100 mg/ml streptomycin and 100 units/ml penicillin.
Cells trypsinized by trypsin-EDTA (0.25%, GIBCO) were used
for subculture and plating. The cytotoxicity of CEL, MC and
MCS against MDA-MB-231 cells was evaluated by MTT assay.
Cells were seeded into 96-well plates at a density of
1  104 cells/well and incubated for 24 h. Samples which
contained CEL, MC and MCS with fresh culture media were
added to the cells in different concentrations ranging from
0.1 mg/ml to 50 mg/ml and samples without these were used as
a control. After a 24 h-incubation, the volumes removed were
replaced with fresh culture medium followed by the addition
of 20 ml/well of MTT solution (5 mg/ml). After another 4 h of
incubation, the medium was replaced with DMSO. Then, the
plates were gently shaken for about 10 min to ensure that the
formazan was completely dissolved. The absorbance was
determined at 570 nm with a microplate reader (ELX 800; BIO-
TEK Instrument, Inc.) and the cell viability (%) was calculated
from the following equation: Cell viability (%) ¼ (ODsample/
ODcontrol) 100, ODsample represents the results from the wells
treated with different samples and ODcontrol represents the
wells treated with DMEM alone.
2.6.2. Migration and invasion assay
The migratory capacity of the cells was measured by the
transwell chamber test using cell culture inserts (6.5 mm,
Corning, NY). Cells (5  104 cells) were suspended in serum-
free medium and mixed with different test solutions (10 mg/
ml CEL, 40 mg/mlMC and 40 mg/mlMCS), and then injected into
the upper chamber. The complete DMEM medium with the
above test solution in the bottom chamber was separated
from the cells by a polycarbonate membrane (8.0 mm). After a
24 h-incubation, the cells which had not migrated to the un-
dersurface of the membrane filter were completely removed
using a cotton bud. The cells that had migrated through the
membrane were fixed with 75% ethanol and stained with
crystal violet for 30 min. Then, they were washed with PBS
three times. The stained cells were visualized and photo-
graphed using a fluorescence microscope (Olympus, Japan).
Finally, the stained cells were soaked in acetic acid for 20 min
and stainedwith crystal violet solution. The absorbance of the
crystal violet solutions was measured at 595 nm using a
microplate reader (ELX800, BIO-TEX Instrument, Inc.). The
inhibition ratio (%) was calculated from the following equa-
tion: The inhibiting ratio (%) ¼ ODcontrol e ODsample/
ODcontrol  100, ODsample represents the results from cells
treated with CEL, MC or MCS, and ODcontrol is from untreated
cells.
Cell invasion behavior was analyzed using transwell cell
culture inserts coated with matrigel. Cells (5  104 cells) sus-
pended in serum-freemediumwere treatedwith different test
solutions and transferred to the upper chamber. All the other
operations were the same as those in the migration experi-
ment. The stained cells were also photographed with a fluo-
rescence microscope and the absorbance was measured at
595 nm using a microplate reader.
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MDA-MB-231 cells were seeded at a density of 5  104 cells in
24-well plates. The cells were given a uniform scratch using a
micropipette tip when they grew into a monolayer film and
adhered to the well, and then washed with PBS until no dead
cells remained. Fresh complete medium containing samples
(CEL, MC and MCS) with the same concentration of CEL (10 mg/
ml) were added to the cells and those without added samples
were used as a control. Cells were allowed to migrate to the
scratch area and heal the wound for 0, 12 and 24 h. Wound
closure was photographed using a fluorescence microscope
(Olympus, Japan) at 0, 12 and 24 h.3. Results and discussion
3.1. Characterization of MC carrier
In the current test, the preparation of carbon material was
carried out using the hard template method. Face-centered
cubic mesoporous silica as a template was used to construct
mesoporous carbon with converse pore structure. The pore
channels of mesoporous carbon were transformed from the
pore walls of templates. The morphology of the samples
(carriers, drugs and drug loaded samples) was studied by SEM
and TEM. As seen in Fig. 1A, MC exhibited a hexagonal
structure and about 5 mm of particle size. To study mesoporeFig. 1 e SEM images of (A) MC and (B) CELstructure of MC, a part of MC was amplified by TEM. The
mesoporous structure of MC can be clearly seen from Fig. 1C.
MC had a clear 3-dimensional pore structure. Uniform pore
channels of MC were arranged in a highly ordered array.
Furthermore, the pore volume and the pore size of MC were
high up to 1.51 cm3/g and 9.74 nm, respectively (Table 1).
3.2. Drug loading and characterization
As seen as in Fig. 1B, bulk crystalline and irregular shape CEL
beforedrug loadingwasshowedbySEM.Asseenas inFig. 1D, in
contrast with unloaded MC, most of the pore channels in MCS
were visible, but they were not clear as MC, indicating that a
large number of the pore-channels of MC had been filled with
CEL. Moreover, disappearance of bulk crystalline drugs also
indicated that theywere incorporated into theporesof carriers.
Theweight of CEL loaded in theMCS,MCAandMCPwas 18.1%,
15.5% and 19.9% using ultraviolet (UV) spectroscopy, respec-
tively (Table 1). However, the practical drug loading (18.1%) of
MCS was different from the expected drug loading (20%). The
mainly reason for this phenomenonwas that somedrugswere
lost during drug loading and washing process.
3.3. Nitrogen adsorption analysis
The N2 adsorption tests were carried out to investigate the
pore structure characteristics of samples. As shown in Fig. 2,. TEM images of (C) MC and (D) MCS.
Table 1 e Results of nitrogen adsorption analysis and
drug loading.
Sample SBET
(m2/g)
Vt
(cm3/g)
Pore
size (nm)
Degree of
drug loading (%)
MC 751.32 1.51 9.74
MCS 176.01 0.42 7.80 18.1%
MCA 362.16 0.35 3.45 15.5%
MCP 372.60 0.94 7.50 19.9%
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hysteresis loop and IV isotherms, according to the IUPAC
classification. Furthermore, the pore size distribution profiles
confirmed that MC had a uniform pore size (Fig. 2). The result
was also confirmed by the BET analysis. Table 1 shows thatMC
had a uniform pore size of 9.74 nm. The shape of the hyster-
esis loop for MCP was almost the same as that of MC, indi-
cating that physical mixing process did not produce a
significant effect on the pore structure. There were some
changes of the shape of the hysteresis loop for MCS and MCA.
This was due to that some pore spaces were occupied by drug
molecules and their structure was changed after the drug
loading. The data on the surface area (BET), pore volume (Vt)
and BJH pore diameter (WBJH) were shown in Table 1. A sig-
nificant reduction of the pore volume and surface area for
MCS and MCA indicated that some pore spaces were occupied
by drug molecules and the successful drug loading was
completed. However, the pore volume area for MCS did not
show a significant reduction due to that some of drugs were
not loaded into the pore channels during the physical mixing
process. Additionally, to study the relationship between the
occupation volume and dispersion of drug molecules, the
equation (Volume occupation ratio (%) ¼ (wt%CEL/MMolar
mass)  NAvogadro’s constant  VMolecule volume/VPore volume) was
used to calculate the volume occupation ratio of CEL loaded on
MCS. The theoretical volume occupation ratio of CEL loaded
on MCS is just 5.1% according to the practical drug loading
(18.1%). However, the practical volume occupation ratio of CEL
loaded onMCS andMCAwas 72.2% and 76.8%, estimated from
the results of nitrogen adsorption analysis (Table 1). It was
worth noting that the practical volume occupation ratios of
72.2% and 76.8% were significantly higher than the theoretical
volume occupation ratio of 5.1%. It indicated that drug mole-
cules of MCS and MCAwere all not closely arranged inside the
pores. Furthermore, some pore windows or pore channelsFig. 2 e Adsorptionedesorption isotherms and poremay be blocked by them. Drug molecules did not closely pack
in the pores, which resulted in the production of unoccupied
space. This meant that their resistance in the release process
may be reduced.
3.4. Solid state characterization
XRD measurements were carried out to study the crystal
properties of samples. As shown in Fig. 3, eight main charac-
teristic peaks of pure CELwere found at 14.8, 16.1, 19.7 21.5,
23.4, 24.6, 25.3 and 29.4, respectively. Comparatively, no
any of the above-mentioned peaks was shown in the XRD
patterns of MC. The main diffraction peaks of MCP were still
preserved but weakened. This showed that the crystalline
form of CEL was partly covered up by MC. However, MCA and
MCS did not show any diffraction peaks. The drug was in a
non-crystalline state if all the characteristic peaks of drugs
were not present [24,25]. So it was inferred that the crystalline
form was completely covered up and transformed into a non-
crystalline state.
DSC is a sensitive method for detecting crystalline char-
acteristics of the samples. As shown in Fig. 4, a sharp endo-
thermic melting peak at about 161 C for CEL was shown due
to its melting point. In contrast, there was no corresponding
peak for MC at the same temperature. Additionally, the MCP
also had a same but weak endothermic peak, which was due
to that MC did not completely cover up the crystalline form of
CEL. It is worth noting that themelting peak for MCA andMCS
was both not present at about 161 C. The results were in good
agreement with the above XRD results of MCA and MCS. This
indicated that MC could successfully cover up the crystalline
form of CEL, which was due to that CEL could be effectively
loaded into the mesoporous channels of MC using the
adsorption or solvent evaporatedmethod. Furthermore, it has
been reported that some drugs loaded by mesoporous mate-
rials could be maintained in the noncrystalline state due to
space confinement of nanopores [26,27].
3.5. In vitro drug dissolution
In vitro drug dissolution tests were conducted to investigate
the impact of MC on the dissolution rate of CEL. As shown in
Fig. 5, the accumulated percentage of CEL released from pure
CEL within 60minwas just 30.8%, reflecting its poor solubility.
Dissolution behavior of MCP exhibited no significantsize distributions of MC, MCS, MCA and MCP.
Fig. 3 e XRD patterns of MC, MCS, MCA, MCP and CEL.
Fig. 5 e In vitro dissolution profiles for MCS, MCA, MCP and
CEL.
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stayed on the surface of MCwhen theywere physicallymixed,
which resulted in the presence of the crystalline form of MCP.
However, the cumulative release ofMCA andMCS after 60min
was both about 3 times higher than that of pure CEL. This
result was due to that CEL was confined to the narrow spaces
of the mesoporous carbon. Formation of a crystalline form
was difficult, which maintained CEL in the non-crystalline or
amorphous state, and this is shown in Fig. 1B and D. InFig. 4 e DSC patterns of MC, MCS, MCA, MCP and CEL.contrast to the crystalline form, the formation of the
noncrystalline state or amorphous form could significantly
increase the apparent solubility and dissolution rate of poorly
water-soluble drugs [28]. So, the noncrystalline state of CEL
was one of the reasons for its improved dissolution. It was
worth noting that the cumulative release for MCS within the
5 min was up to 51.86%, which was higher than that of CEL
(lower than 45%) loaded into mesoporous carbon reported in
previous studies. This could be due to that the pore size and
pore volume both played a very important role in improving
the dissolution for the poorly soluble drugs. The drug release
process in the mesoporous materials can be described by the
dissolved and released process. On one hand, the dissolved
process was that the drug molecules were dissolved by the
dissolution medium. The pore volume decided the volume of
dissolution medium penetrated to the pore channels. So MC
with pore volume (1.51 cm3/g) could dissolve more drug mol-
ecules, compared with othermesoporous carbon carriers with
relatively small pore volume (1.09 cm3/g). On the other hand,
the released process was that the drug molecules in the
dissolution medium were released from the pores channels.
The possibility of escaping from the pore channels for the
drug molecules was determined by the pore size. Obviously,
drugmolecules inMC (9.74 nm)would havemore chance to be
released from the pore channels, compared with other mes-
oporous carbon carriers with relatively small pore size
(7.0 nm). Additionally, MC with three dimensional inter-
connected pore structure could reduce the diffusion resis-
tance of the dissolution medium and facilitate drugs release.
So, MC with pore volume (1.51 cm3/g) and pore size (9.74 nm)
can be used as an effective delivery vehicle for CEL to allow
their controlled release.3.6. MDA-MB-231 cell experiments
3.6.1. Cytotoxicity assays
The cytotoxicity of CEL, MC, MCS for MDA-MB-231 cells are
shown in Fig. 6. MC was essentially weakly cytotoxic to MDA-
MB-231 cells with a cell viability over 80% even at a concen-
tration of 50 mg/ml, confirming that MC was not significantly
toxic to MDA-MB-231 cells. It was worth noting that the cell
viability of CEL and MCS gradually decreased (CEL:
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range from 0.1 mg/ml to 50 mg/ml, but not significantly. More-
over, cytotoxicity of MCS on cells was slightly stronger than
that of CEL in the same concentration.
3.6.2. Migration and invasion analysis
In order to investigate the effect of CEL, MC and MCS on MDA-
MB-231 cell migration and invasion, a transwell migration test
and invasion assay were carried out to assess the migration
and invasion of cells in response to their use. As shown in Figs.
7 and 8A, many cells migrated through the transwell mono-
layer were showed due to the full staining with crystal violet.
It was concluded that the culture medium was assisted cell
migration after a 24 h-incubation.MDA-MB-231 cells exhibited
significant migration and invasion activity on their own [29].
Then we examined the inhibitory effect of pure CEL on cell
migration and invasion. Treatment with raw CEL reduced the
crystalline purple area meaning that the number of migrated
cells had decreased, compare with the control (Figs. 7 and 8C).
It has been previously reported that CEL inhibited the migra-
tion and invasion of MDA-MB-231 cells, accompanied by
regulation of cyclooxygenase-2 (COX-2) [4]. We loaded CEL
into the pore internal of MC and performed migration and
invasion experiments using MCS to investigate whether MC
can affect the inhibitory capacity of CEL on cell migration and
invasion. In particular, the small crystal violet area showed
that cell migration had been significantly inhibited by MCS
(Fig. 7D). The number of MDA-MB-231 cells invaded through
the filter containing matrigel also declined more significantly
in response to MCS treatment compared with that of cells
treated with pure CEL (Fig. 8D). Compared with the CEL
treatment group, the smaller area of crystal violet showed that
MCS produced a more significant inhibition than that of pure
CEL. These results were also supported by data in Figs. 7 and
8E, we also saw that the migration inhibition rate of MCS
(77.1%) on cells was higher than that of CEL (33.9%) from the
migration inhibition curve (Fig. 7E). Invasive inhibition ca-
pacity of MCS (80.9%) on MDA-MB-231 cells was also higher
than that of pure CEL (50.8%) (Fig. 8E). Themigration inhibition
rate and the invasion inhibition rate of MDA-MB-231 cells
treated with MCS was increased by 2.27-fold and 1.59-fold
respectively compared with non-treated MDA-MB-231 cells.
So, we concluded that MCS markedly inhibited the migrationFig. 6 e Cytotoxicity of MC, CEL and MCS on MDA-MB-231
cells at different concentrations (0.1, 1, 5, 10 and 50 mg/ml).and invasion of MDA-MB-231 cells and its inhibitory effect
was higher than that of CEL.
Subsequently, the main reasons for the improved inhibi-
tory effect of CEL on the migration and invasion of MDA-MB-
231 cells were systematically studied. MTT tests were car-
ried out to investigate the possibility that the inhibitory effect
of MCS on cell migration and invasion was due to its toxic
effect on cell viability. MDA-MB-231 cells were treated with
MCS or CEL at a concentration of 10 mg/ml for 24 h. The results
obtained showed that cell viability treated by MCS was not
significantly different from that by CEL when the concentra-
tion was 10 mg/ml (Fig. 6). So, it can be excluded that their
cytotoxicity was the main reason for inhibiting cell migration
and invasion. Then, in order to study the relationship between
MCS and MC for anti-tumor metastasis ability, we investi-
gated the impact of MC on migration and invasion of MDA-
MB-231 cells. The results obtained showed that MC had
almost no effect on cell migration and invasion due to its
migration and invasion inhibitory rate of less than 20% (Figs. 7
and 8B, E). So, we excluded the possibility that MC can inhibit
the metastasis of MDA-MB-231 cells. Therefore, we can spec-
ulate that the main reason that the inhibition of MCS was
higher than that of pure CEL for MDA-MB-231 cell metastasis
may be due to the dissolution of raw CEL increased by MC. It is
well known that the poor solubility of raw CEL limited its ef-
ficacy. Therefore, improvement in the solubility of CEL could
play a crucial role in the increased pharmacodynamic efficacy.
Improvement in the dissolution rate can increase the con-
centrations of drug in MDA-MB-231 cells. Furthermore, the
surface area of the drug particles at the nano-level was
markedly higher than that of the raw drug. In other words, the
drug nanoparticles released from MC increased the contact
area of the drug with the MDA-MB-231 cells, and thus pro-
duced a better inhibitory effect. In summary, these combined
results indicate that MCS markedly inhibits migration and
invasion of MDA-MB-231 cells and its inhibitory capacity was
higher than that of CEL. Dissolution enhancement of CEL may
be the main reason that MCS significantly inhibited cell
migration and invasion. Moreover, CEL was dispersed into
nanoparticles after being loaded into the mesopores of MC.
Then, the CEL nanoparticles were released from the MC and
absorbed by MDA-MB-231 cells. It was well-known that
nanoparticles could increase the absorption by cells [30]. So
the increased absorption for CEL may be another reason for
improving the inhibition of cell migration and invasion.
In recent years, carbon materials have begun to be applied
to the field of drug delivery system [31e33]. However, as far as
we known, there have been almost no reports on the appli-
cation of mesoporous carbon to treat anti-tumor metastasis.
MC was used in our research into anti-tumor metastasis for
the first time. When MC was used as a drug carrier it effec-
tively increased the dissolution of CEL and improved its
therapeutic effect. So, MC appears to be a promising drug
carrier for anti-tumor metastasis with significant advantages
such as low cytotoxicity, high adsorption and uniform pore
size.
3.6.3. Wound-healing assay
The wound-healing test was also carried out to further eval-
uate the inhibition capability of MC, CEL and MCS on cell
Fig. 7 e Fluorescence microscopy images of migrated MDA-MB-231 cells through transwell culture inserts membrane
incubation with serum-free medium (A), serum-free mediummixed with MC (B), serum-free mediummixed with CEL (C),
serum-freemediummixedwithMCS (D), Themigration inhibiting ratio ofMC,CEL,MCSonmigrationofMDA-MB-231 cells (E).
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width was significantly reduced after a 12 h-incubation. It is
worth noting that the scratch had completely healed after a
24 h-incubation, which suggested that the MDA-MB-231 cells
themselves exhibited a high migration. As seen in Fig. 9DeF
(MC treatment group), the cells with MC treatments healed
thoroughly after treatment for 24 h. These results were sub-
stantially the same as those of the control group, indicating
that MC had no significant effect on motility of cells in vitro.
As shown in Fig. 9GeI (CEL treatment group) and Fig. 9JeL
(MCS treatment group), wounds treated with CEL and MCS
remained cracked and their width was significantly wider
than those of the control group after a 24 h-incubation, indi-
cating that cell migration was significantly inhibited after
treatment with CEL and MCS. In addition, the scratch width
treated with MCS was apparently wider than that of pure CEL,
which demonstrated that migratory inhibitory effect of MCS
on MDA-MB-231 cells was more potent than that of CEL. The
result that the motility of MDA-MB-231 cells treated with MC
could not be inhibited suggested that the anti-motile activityFig. 8 e Fluorescence microscopy images of invaded MDA-MB-2
membrane incubation with serum-free medium (A), serum-free
with CEL (C), serum-free medium mixed with MCS (D), The inva
MB-231 cells (E).of MCSwas no account of synergistic actions betweenMC and
CEL. These results also supported the conclusions of the above
migration and invasion experiment.4. Conclusion
The results of this paper showed that mesoporous carbon
with a large pore volume (1.53 cm3/g) and large pore size
(9.74 nm) was successfully prepared. Celecoxib was success-
fully loaded into MC using three different methods. According
to the results of DSC and XRD experiments, MCS and MCA
could completely cover up the crystalline form of CEL, while
the MCP could partly covered up the crystalline form of CEL.
The dissolution study showed that the dissolution rate of CEL
released from MCS and MCA was all significantly higher
compared with that of raw CEL. It was excited that the accu-
mulated release for MCS within the 5 min was up to 51.86%.
Furthermore, the results of the migration, invasion and
wound-healing assays all indicated that MCS enhanced the31 cells through transwell culture inserts matrigel
medium mixed with MC (B), serum-free medium mixed
sion inhibiting ratio of MC, CEL, MCS on invasion of MDA-
Fig. 9 e Fluorescence microscopy images of scratched MDA-MB-231 cells incubation with complete medium for 0 h (A), 12 h
(B), 24 h (C), complete medium contained MC for 0 h (D), 12 h (E), 24 h (F), complete medium contained CEL for 0 h (G), 12 h (H),
24 h (I), complete medium contained MCS for 0 h (J), 12 h (K), 24 h (L).
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 8 2e9 190inhibitory effect of CEL on themigration and invasion of MDA-
MB-231 cells, whichmay be due to the improved dissolution. It
was expected that the application for MC in the field of anti-
tumor metastasis could open up new opportunities for mes-
oporous carbon as a carrier.
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